Positive topline data from Viking Therapeutics VK2735 maintenance period has landed with a muted reaction. Week 33 results show continued weight loss with no plateau and a clear separation from placebo. VKTX stock fell anyway. The disconnect raises questions about how capital markets price obesity assets in late 2025.
💡 Frequently Asked Questions (FAQ)
- Q: Why did VKTX stock fall after positive week 33 weight loss data?
- A: Despite strong efficacy, investors appeared to price in competitive pressure from GLP-1 leaders, commercialization and manufacturing risks, durability questions, and broader biotech valuation fatigue.
- Q: What were the week 33 results for Viking Therapeutics VK2735?
- A: Week 33 results showed continued weight loss with no plateau and clear separation from placebo during the maintenance period, supporting durability of VK2735.
- Q: Is a muted reaction common for obesity drug stocks?
- A: Yes, late-stage obesity assets often see muted or negative market reactions due to high expectations, pricing hurdles, safety scrutiny, and intense competition.